Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia
Recruiting
Phase 2
Interventional Study
Fronto-temporal Dementia
Fronto-temporal Lobar Dementia
Frontotemporal Degeneration
Frontotemporal Dementia (FTD)
Frontotemporal Dementia, Behavioral Variant
Frontotemporal Dementia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 45 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 50 (estimated)
- Sponsor
- Johns Hopkins University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to learn if vortioxetine improves mood symptoms and cognition in patients with early-stage behavioral variant Frontotemporal Dementia (bvFTD). The main questions this study aims to answer are:
1. Do individuals with mood symptoms and bvFTD have brain changes and cognitive profiles that differ compared to individuals without bvFTD?
2. Do mood symptoms and cogniti…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
FTD Patients
Inclusion Criteria:
1. Male or Female
2. Age 45 and above
3. Diagnosis of possible or probable bvFTD based on international consensus criteria for behavioral variant FTD (FTDC)
4. The presence of at least one of the following affective symptoms on the 12-item Neuropsychiatric Inventor…
Contacts